共 289 条
- [1] Ferlay J(2015)Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 136 359-386
- [2] Soerjomataram II(2018)EASL clinical practice guidelines: management of hepatocellular carcinoma J Hepatol 69 182-236
- [3] Dikshit R(2009)Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma Clin Cancer Res 15 971-979
- [4] Eser S(2016)Adjuvant sorafenib in hepatocellular carcinoma: a cautionary comment of STORM trial World J Hepatol. 8 957-960
- [5] Mathers C(2015)Immune checkpoint blockade: a common denominator approach to cancer therapy Cancer Cell 27 450-461
- [6] Rebelo M(2014)Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions Hepatology 60 1776-1782
- [7] Gao Q(2009)Intratumoural GM-CSF microspheres and CTLA-4 blockade enhance the antitumour immunity induced by thermal ablation in a subcutaneous murine hepatoma model Int J Hyperth 25 374-382
- [8] Wang XY(2010)Antigen-presenting cell function in the tolerogenic liver environment Nat Rev Immunol 10 753-766
- [9] Qiu SJ(2012)The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 252-264
- [10] Yamato I(2017)Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Lancet 389 2492-2502